Archives
-
Sulfo-Cy5 Carboxylic Acid for Immune Imaging
2026-10-09
Sulfo-Cy5 carboxylic acid offers a water-compatible far-red signal for protein and peptide labeling and fluorescence imaging. This article explains how its properties can support interpretation of nanoparticle biodistribution and mucosal-immunity studies without confusing fluorescent localization with biological mechanism.
-
Dexamethasone: Reading Evidence Across Cell Models
2026-10-09
Dexamethasone is a glucocorticoid anti-inflammatory used to study NF-κB regulation, stem cell fate, autophagy, and neuroinflammation. This evidence-centered guide separates reported findings from interpretation and explains how to compare results across cellular and animal models.
-
A 83-01 and the Translational Logic of TGF-β Biology
2026-10-08
A mechanistic perspective on how A 83-01, an ALK-5 inhibitor, can help translational researchers distinguish TGF-β pathway activity from YAP1-linked hepatocyte stemness while respecting evidence boundaries.
-
Camostat Mesilate: Mechanism and Evidence Map
2026-10-08
Camostat Mesilate is a trypsin-like protease inhibitor with research relevance spanning ENaC regulation, plasmin–TGF-β biology, and fibrosis. This evidence-focused guide distinguishes its established mechanistic uses from emerging TMPRSS2-directed macrocycle research.
-
Mianserin Hydrochloride: Evidence From a 1976 Trial
2026-10-07
The 1976 British Journal of Psychiatry study evaluated mianserin hydrochloride against amitriptyline while integrating antidepressant efficacy, adverse effects, and plasma drug measurement. Its main contribution was not a receptor-mechanism demonstration, but a clinically oriented framework showing similar apparent antidepressant benefit, fewer reported side effects with mianserin, and no clear relationship between plasma concentration and therapeutic response.
-
Frizzled5 Cholesterol Sensing Links Wnt to Cancer
2026-10-07
Zheng and colleagues reported that Frizzled5 can bind cholesterol through its extracellular linker, connecting sterol metabolism with receptor maturation, Wnt/β-catenin signaling, and pancreatic ductal adenocarcinoma growth. The study offers a mechanistic framework for understanding how lipid availability can regulate a morphogen receptor, while its therapeutic implications remain dependent on cancer subtype and further validation.
-
Ferrostatin-1: Evidence, Uses, and Limitations
2026-10-06
Ferrostatin-1 (Fer-1) is a research tool used to investigate ferroptosis and oxidative lipid damage. Evidence from a 2024 mouse-ovary study supports a role for ferroptosis in DEHP-associated injury, while also showing why Fer-1 rescue data require cell-, tissue-, and model-specific interpretation.
-
AZ505 and SMYD2 Inhibition: Evidence and Limits
2026-10-06
This source-grounded overview answers five questions about AZ505 as an SMYD2 inhibitor: its biological principle, what potency and selectivity mean, what the cisplatin-induced kidney disease study found, how strong the evidence is, and where the findings should not be extrapolated.
-
CCR7–Notch1 Crosstalk in Mammary Cancer Stemness
2026-10-05
Boyle et al. reported that CCR7 signaling functionally intersects with Notch1 activity in primary MMTV-PyMT mammary tumor cells, linking two regulatory axes associated with cancer stem-like behavior. The study provides preclinical evidence for pathway crosstalk, while its mouse-model design limits direct conclusions about human breast cancer treatment.
-
Berberine, SIRT6-AMPK, and Atrial Fibrillation
2026-10-05
A 2026 International Immunopharmacology study links impaired SIRT6-AMPK signaling with angiotensin II-induced atrial remodeling and shows that berberine suppresses NLRP3 inflammasome activation in a murine model. The findings support a mechanistic connection between metabolic signaling, oxidative stress, inflammation, fibrosis, and atrial fibrillation susceptibility, while remaining preliminary for human treatment.
-
5-Azacytidine in Myeloma: ATR and Synergistic Cytotoxicity
2026-10-04
The 2007 reference study connected 5-azacytidine exposure with ATR-associated DNA double-strand break responses, apoptosis, and enhanced cytotoxicity with doxorubicin or bortezomib in multiple myeloma models. Its main contribution was to broaden the interpretation of a DNA methyltransferase inhibitor from epigenetic modulation alone to a compound capable of producing therapeutically relevant DNA damage in treatment-resistant disease models.
-
Isorhamnetin: From Oocyte Biology to Translation
2026-10-03
A source-grounded analysis of Isorhamnetin as a mechanism-linked research compound in porcine oocyte maturation, with emphasis on PI3K/Akt signaling, oxidative stress, apoptosis, translational evidence boundaries, and strategic study design.
-
Ferrostatin-1 (Fer-1) Experimental Workflows
2026-10-01
Ferrostatin-1 (Fer-1) provides a practical rescue control for distinguishing lipid peroxidation-driven ferroptosis from nonspecific cytotoxicity. This workflow guide covers dose finding, assay design, translational comparisons, and troubleshooting across cancer biology research, neuronal models, and injury-focused experiments.
-
Sulfo-Cy3 NHS Ester for Vascular Labeling
2026-10-01
Sulfo-Cy3 NHS Ester combines water compatibility with efficient amine-reactive labeling, making it useful for soluble proteins, low-solubility targets, endothelial uptake assays, and controlled bioconjugation. This guide translates the AIBP-LRP2 vascular remodeling findings into practical labeling, imaging, quality-control, and troubleshooting workflows.
-
Ferrostatin-1 and Cuproptosis: A Translational Lens
2026-09-30
Ferrostatin-1 (Fer-1) is more than a ferroptosis inhibitor: it is a precision tool for separating lipid peroxidation from other metal-associated death programs. This article examines how Fer-1 can sharpen mechanistic interpretation across cancer biology, neurodegenerative disease models, and emerging parasite research without confusing ferroptosis with cuproptosis.